Single-EV Analyses Require Rigorous Antibody Qualification: PD-L1 Profiling in Cell Models and Patient Plasma
Tobias Tertel1, Fabiola Nardi Bauer1,2, Oumaima Stambouli1
1Institute for Transfusion Medicine University Hospital Essen University of Duisburg-Essen Essen Germany.
Antibody performance is crucial for imaging flow cytometry (IFCM) of extracellular vesicles (EVs). This study developed a validated IFCM workflow for detecting PD-L1 positive EVs in patient plasma, highlighting the need for application-specific antibody validation.
Area of Science:
- Extracellular vesicle (EV) research
- Immunophenotyping
- Biomarker discovery
Background:
- Imaging flow cytometry (IFCM) offers high-throughput, single-vesicle analysis of extracellular vesicles (sEVs).
- Antibody performance is critical for IFCM reliability and sensitivity in sEV detection.
- Existing antibody validation for cellular targets may not translate to sEV analysis.
Purpose of the Study:
- To systematically compare commercial anti-PD-L1 antibodies for sEV detection using IFCM.
- To develop and validate a standardized IFCM workflow for sEV profiling.
- To assess the potential of IFCM for semi-quantitative analysis of PD-L1 positive sEVs in patient plasma.
Main Methods:
- Systematic comparison of anti-PD-L1 antibodies for labeling PD-L1 positive sEVs.
- Development of a robust IFCM workflow adhering to MIFlowCyt-EV standards.
- Application of the validated workflow to analyze PD-L1 positive sEVs in unprocessed plasma from cancer patients and healthy donors.
- Comparison of IFCM with bead-based methods and dilution experiments for quantitative assessment.
Main Results:
- Significant differences in labeling efficiency were observed among anti-PD-L1 antibodies from different manufacturers.
- A validated IFCM workflow enabled reproducible detection of PD-L1 positive sEVs in patient plasma.
- IFCM demonstrated semi-quantitative capability by revealing distinct PD-L1 positive sEV levels, unlike bead-based methods.
- Elevated PD-L1 positive sEV levels were detected in plasma subsets from head and neck, lung, and breast cancer patients.
Conclusions:
- Antibody suitability for sEV analysis requires rigorous, application-specific validation beyond standard cellular assays.
- A standardized IFCM workflow provides a reliable method for single-EV profiling.
- Elevated PD-L1 positive sEVs in cancer patient plasma suggest potential clinical relevance.
- The quality of antibodies is paramount for accurate analytical results in single-EV studies.
More Related Videos
10:18Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
